Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) EBITDA (2018 - 2025)

Historic EBITDA for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$705775.0.

  • BioNexus Gene Lab's EBITDA fell 13637.64% to -$705775.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 1229542.8%. This contributed to the annual value of -$1.5 million for FY2024, which is 4905.39% up from last year.
  • BioNexus Gene Lab's EBITDA amounted to -$705775.0 in Q3 2025, which was down 13637.64% from -$249094.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's EBITDA registered a high of $431764.0 during Q4 2023, and its lowest value of -$2.6 million during Q3 2023.
  • In the last 5 years, BioNexus Gene Lab's EBITDA had a median value of -$249094.0 in 2025 and averaged -$317184.3.
  • As far as peak fluctuations go, BioNexus Gene Lab's EBITDA soared by 73114.54% in 2021, and later crashed by 229496.97% in 2022.
  • BioNexus Gene Lab's EBITDA (Quarter) stood at $128173.0 in 2021, then surged by 88.31% to $241359.0 in 2022, then soared by 78.89% to $431764.0 in 2023, then tumbled by 346.75% to -$1.1 million in 2024, then skyrocketed by 33.75% to -$705775.0 in 2025.
  • Its EBITDA stands at -$705775.0 for Q3 2025, versus -$249094.0 for Q2 2025 and -$551168.0 for Q1 2025.